Radiopharm Theranostics Limited ("RAD") filed a Form 6-K noting that it has received Investigational New Drug (IND) approval from the U.S. FDA for its radiopharmaceutical candidate Betabart (RV-01). The information, first released to the Australian Securities Exchange on 28 July 2025, marks a key regulatory milestone that permits RAD to proceed with U.S. clinical studies. No financial figures, study design specifics, timelines or guidance were provided in this filing.
Radiopharm Theranostics has filed a Form 6-K to report the signing of a significant supply agreement with Cyclotek for 161Tb-KLK3-mAb, as announced on the Australian Securities Exchange on June 24, 2025.
The filing consists of an announcement made to the Australian Securities Exchange regarding the supply agreement, which has been attached as Exhibit 99.1 to the Form 6-K. The company files annual reports under Form 20-F and is not subject to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
This Form 6-K and its exhibits are not considered "filed" for Securities Exchange Act purposes and will not be automatically incorporated by reference into future securities filings unless specifically referenced. The document was signed by Company Secretary Phillip Hains.